
Differin
Schering Health Care Limited. Mirena. Summary of Product Characteristics 2001. 2. Anon. Which operation for menorrhagia? DTB 2000; 38: 77-80. Anon. Levonorgestrel intra-uterine system for menorrhagia. DTB 2001; 39: 85-7. The primary outcomes, evaluated at 1, 2, 3, and 5 4. Prentice A. Medical management of menorrhagia. BMJ years, were: pregnancy due to method or user failure; and 1999; 319: 1343-5. continuation of the contraceptive method. The pooled 5. Royal College of Obstetricians and Gynaecologists. The initial management of menorrhagia. Royal College of Obstetricians and rate ratios for pregnancy were not significantly different Gynaecologists. 1998. between L -IUS and copper-releasing IUDs with a surface 6. French R, Cowan F, Mansour D, Morris S, Procter T, et al. area of 250mm2 eg CuT380A, CuT380Ag ; but were Implantable contraceptives subdermal implants and hormonally significantly lower in L-IUS users compared with users of impregnated intrauterine systems ; versus other forms of 2 IUDs with surface area 250mm eg Nova-T, CuT200, reversible contraceptives: two systematic reviews to assess CuT 220 ; . Continuation rates in L -IUS users were not relative effectiveness, acceptability, tolerability and costsignificantly different from copper IUD 250mm2 users. effectiveness. Health Technology Assessment 2000; 4. 7. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The At 5 years, IUD 250mm2 users were less likely to effectiveness of the levonorgestrel-releasing intrauterine continue with the contraceptive method than users of Lsystem in menorrhagia: a systematic review. Br J Obstetrics & IUS, although this difference between treatment was not Gynaecology 2001; 108: 74-86. evident at earlier time points. 8. Hurskainen R, Teperi J, Rissanen P, Aalto A, Grenman S, et al. Quality of life and cost-effectiveness of levonorgestrelreleasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273-7. Date: April 2002 SS02 05 THIS SUMMARY SHEET REPLACES SS96 04 WHICH SHOULD BE REMOVED AND DESTROYED MTRAC, Department of Medicines Management, Keele University. An incident report will be completed for each incident reported, and a copy of the form will be sent to the agency Incident Review Committee. A copy of the incident report form is filed in the case record of all tenants involved in the incident. Whenever a law enforcement officer arrives in response to a call, the staff member handling the incident should take the badge number of the officer and include this information in the incident report. Any incident that involves Emergency Medical Service EMS ; should be documented and include names, telephone numbers, or other identifying information of EMS staff or emergency room personnel, including phone contacts, for example, benzaclin differin. I do hope the differin works for you, but don't lose hope if it starts not to work, sometimes it's just a matter of finding the right combination of products. FIGURE 7. Comparison of the displacement of 2 nM [3H] 5HT by 5-MT 100 fjM 8-OH-DPAT 100 nM 8-OH-DPAT 100 nM ; + RU24969 100 nM 8-OH-DPAT 100 nM ; + mesulergine 100 nM ; and 8-OH-DPAT 100 nM ; + sumatriptan 100 nM ; . Results are SEM, where n 3. opment of better ligands and the recent availability of a new, high-specific activity [3H] 5-HT salt, have given us the opportunity to characterize more fully the serotonin receptor subtypes present in the rabbit iris-ciliary body. The heterogeneity of serotonin receptors was revealed by radioligand binding studies using [3H] 5-HT.20"23 [3H] 5-HT has been the most widely used label for the characterization of serotonin receptors because of its high affinity for all the 5-HT, receptors and the 5-HT2C and 5-HT2B receptors. Peroutka and Snyder20 showed that 5-HT2 now termed 5-HT2A ; binding sites cannot be labeled with [3H] 5-HT. The current study demonstrates clearly that [3H] 5-HT TFA labels a population of 5-HT1A receptors in the rabbit iris-ciliary body and more specifically in the ciliary processes. The study also finds no evidence for the presence of any other subtypes to which [3H] 5-HT is known to bind. The results confirm the findings of Mallorga and Sugrue8 and Tormay et al24 that 5HT| binding sites exist in the tissue. There are several observations supporting this conclusion. First, inhibition of [3H] 5-HT binding by a range of drugs of differing selectivities yielded the expected pharmacologic characteristics of a 5-HT|A subtype. Thus, not only was the pharmacologic profile of the [3H] 5-HT binding sites consistent with the expected profile of binding to a 5-HT|A subtype, the apparent Kf values of those compounds tested are close to the reported Kj values in tissues containing the 5-HT1A subtype.25 Second, computer modeling indicated the existence of a single class of binding sites for 5-HT with a KD. Differin dryTretinoin 0.1% cream Brands acitretin adapalene alitretinoin azelaic acid acne ; bexarotene gel tazarotene RETIN-A * SORIATANE DIFFERIN PANRETIN AZELEX TARGRETIN TAZORAC and eldepryl. 1. Introduction The pomegranate tree, which is said to have flourished in the garden of Eden, has been extensively used as a folk medicine in many cultures [1]. Content of soluble polyphenols in pomegranate juice varies within the limits of 0.2 1.0%, depending on variety and include mainly tannins, ellagic tannins, anthocyanins, catechins, gallic and ellagic acids [2, 3]. We have recently shown [4] a potent anti-atherogenicity of pomegranate juice consumption in healthy humans and in atherosclerotic mice and identified tannins as the active components responsible for the anti-oxidative properties of pomegranate juice against low-density lipoprotein oxidation [4, 5]. Hypertension is a known risk factor for the development of atherosclerosis and in hypertensive patients with elevated plasma rennin angiotensin activity, a five folds increased incidence of myocardial infarction was demonstrated [6]. The production of angiotensin II. In addition, the increased emphasis on managed healthcare in the united states will put additional pressure on the pricing and usage of any of our products, which may adversely affect product sales and revenues and feldene, for instance, differin gel review. COMPANY Abbott Laboratories, Limited Alcon Canada Inc. Astra Pharma Inc. BRAND NAME HP-Pac 30 500 N.A. 7dkit Patanol 1mg mL Oxeze Turbuhaler 0.012 mg dose Oxeze Turbuhaler 0.006 mg dose Adalat XL 20mg tab Bayer Inc. Baycol 0.2mg tab Baycol 0.3mg tab Cipro 100 mg ml Climara 0.05 3.9mg patch Berlex Canada Inc. Biogen Canada Inc. Climara 0.1 7.8mg patch Levovist Avonex 0.033mg vial Flomax 0.4mg cap Boehringer Ingelheim Canada ; Ltd. Mirapex 0.25mg tab Mirapex 1mg tab Mirapex 1.5mg tab Viramune 200mg tab Avapro 75mg tab Bristol-Myers Squibb Pharmaceutical Group Avapro 150mg tab Avapro 300mg tab Taxol 6mg mL Eli Lilly Canada Inc. Galderma Canada Inc. Zyprexa 2.5mg tab Ditferin 1mg gm Amerge 1mg tab Amerge 2.5mg tab Flovent Diskus 0.05mg dose Flovent Diskus 0.10mg dose Glaxo Wellcome Inc. Flovent Diskus 0.25mg dose Flovent Diskus 0.50mg dose Nimbex 2mg ml Nimbex 10mg ml Retrovir 300mg tab Serevent Diskus 0.05mg dose cisatracurium besylate zidovudine salmeterol xinafoate fluticasone propionate paclitaxel olanzapine adapalene naratriptan hydrochloride irbesartan nevirapine pramipexole dihydrochloride CHEMICAL NAME lansoprazole clarithromycin amoxicillin olopatadine hydrochloride formoterol fumarate nifedipine cerivastatin sodium ciprofloxacin estradiol 17 galactose palmitic acid interferon beta-1a tamsulosin hydrochloride DIN 02238525 02233143 02237224 Adjunct to anesthesia non-depolarizing skeletal neuromuscular blocking agent ; HIV infection antiretroviral agent ; Asthma therapy inhaled corticosteroid ; 18 Aug 1998 21 Sep 1998 5 May 1998 Asthma therapy inhaled corticosteroid ; 5 May 1998 Cancer therapy breast, ovarian, NSCL ; Schizophrenia antipsychotic agent ; Acne therapy topical ; Migraine therapy Jan 1993 patented 12May98 ; 14 Jul 1998 1 Jan 1998 5 May 1998 Hypertension angiotensin II antagonist ; 2 Jun 1998 HIV infection NNRTI ; 17 Sep 1998 Parkinson's disease dopamine agonist ; 29 Jan 1998 Indications Ulcer therapy eradication of Helicobacter pylori ; Allergy therapy ophthalmic preparation ; Asthma therapy long acting 2 agonist ; Angina hypertension calcium channel blocker ; Lipid lowering therapy "statin" ; Antibacterial agent Hormone replacement therapy estrogen patch ; Ultrasound contrast agent cardiovascular ; Multiple sclerosis biological response modifier ; Treatment of benign prostatic hyperplasia alpha-1 blocking agent ; DATE OF FIRST SALE 18 Aug 1998 26 Jan 1998 9 Mar 1998 3 Apr 1998 26 May 1998 27 Aug 1998 1 Dec 1997 23 Apr 1998 25 May 1998 1 Jun 1998. Rise to two divergent receptor proteins, TRa and TRa2. The proteins encoded are identical for the first 370 amino acids and then diverge completely. TRa represents an authentic receptor whereas the protein encoded by TRa2 does not bind hormone. The c-erbA TR 3 gene, which has been mapped to human chromosome 3, encodes at leasttwo receptor isoforms, TR 3, the human c-erbA clone described by Weinberger 3 ; , and TR132, which differs completely at the NH2 terminus but represents a bona fide TR by the criteria of T3 and DNA binding. On the basis of amino acid similarities nd DNA a binding properties, v-ErbA, c-ErbA TRs, and the receptors for retinoic acid retinoic acid receptors, RARs ; and 1, 25-dihydroxycholecalciferol vitamin D3 receptor, VDR ; form a subgroup of the nuclear receptor family 12 ; Fig. 1 ; . Three distinct retinoic acid receptors have been identified in mammals: RARa, RARI3, RAR-y for review see ref 13 ; . Each is encoded by a distinct gene: the human RARa at 17q21, human RARfl at 3p23-24, and human RAR'y on chromosome 12. Further complexity is generated by alternative splicing and or alternativepromoter usage, resulting in the expression of multiple receptor isoforms differing in their NH2terminal sequences. c-ErbA TRs and RARs are highly related in their DNA and ligand binding domains Fig. 1 ; and may have evolved from a common ancestor 12 ; , a hypothesis that is also supported by the similar chromosomal locations l7q2l for TRa and RARa and 3p24r for TR3 and RARI3 ; . RARa expression isfound in numerous tissuesand celllines, whereas RARI3 is expressed in a wide variety of epithelial cell types and RAR-y is expressed primarily in skin. Recently, a second RA response pathway has been identifiedand shown to be mediated by a family of retinoid X receptors RXRs ; 14 ; . RXRs differ from RARs in primary sequence and in their response to retinoids, and appear to play a central role in multiple hormonal signaling pathways by enhancing the DNA binding of VDR, RARs, and c-ErbA TRs 14-18 and frusemide.
Generic allergy relief drugs advair aerolate allegra benadryl bricanyl claritin d decadron dramamine periactin phenergan proventil serevent singulair ventolin zyrtec exelon sumycin diflucan sporanox elimite vermox eskalith haldol lamictal lithobid mellaril prolixin risperdal achromycin amoxyl bactrim biaxin ceclor ceftin ciloxan cipro duricef floxin garamycin keftab levaquin noroxin spectrobid trimox vibramycin zithromax anafranil celexa effexor xr elavil luvox pamelor paxil prozac sinequan tofranil wellbutrin zoloft buspar arava cataflam feldene imuran indocin sr mobic naprelan relafen zyloprim alesse ortho tri cyclen triphasil ditropan leukeran aceon adalat atacand avapro calan capoten cardizem cardura cilexetil combipres cordarone coreg coumadin cozaar diovan esidrix hydrodiuril hytrin hyzaar imdur ismo isoptin isordil lanoxin lasix lisinopril lopressor lotensin lozol minipress moduretic monoket norpace norvasc persantine plavix plendil pletal prinivil prinzide procardia rocaltrol sorbitrate tenoretic ticlid trental vaseretic vasodilan vasotec zebeta zestril lipitor lopid mevacor pravachol zocor actos amaryl avandia diamicron glucophage glucophage sr glucotrol glucotrol xl glucovance micronase prandin precose starlix aldactone microzide oretic dilantin neurontin aciphex bentyl colace cytotec detrol imodium nexium pepcid ac max strength prevacid prilosec protonix reglan zantac zofran propecia proscar combivir epivir retrovir viramune zerit cycrin danocrine deltasone levothroid prednisone provera synthroid altace inderal tenormin vastarel aralen flagyl grisactin myambutol cialis levitra viagra viagra gel viagra soft tabs antivert flexeril flextra ds robaxin soma zanaflex betagan evista fosamax mestinon sandimmune advil anacin celebrex esgic plus fioricet imitrex medipren panadol ponstel pyridium tylenol ultram eldepryl tegretol condylox rebetol zovirax atarax cleocin differin kenalog nizoral retin a synalar temovate ambien zyban compazine meridia aygestin clomid motrin naprosyn nolvadex parlodel serophene generic temovate, clobetasol propionate online price compare generic temovate clobetasol propionate ; buy online temovate, clobetasol propionate is a topical anti-inflammatory medication that helps reduce itching, redness, and swelling associated with many skin conditions.
DIFFERIN isotretinoin RETIN-A liquid 0.05% tretinoin Tier 2 Tier 1 Tier 2 Tier 1 PA PA and keflex.
Tegretol home allergies anti-depressants anti-infectives anti-psychotics anti-smoking antibiotics asthma cancer cardio & blood cholesterol diabetes epilepsy gastrointestinal hair loss herpes hiv hormonal men's health muscle relaxers other pain relief parkinson's rheumatic skin care weight loss women's health allegra atarax benadryl clarinex claritin clemastine periactin phenergan pheniramine zyrtec anafranil celexa cymbalta desyrel effexor elavil, endep luvox moclobemide pamelor paxil prozac reboxetine remeron sinequan tofranil wellbutrin zoloft albenza amantadine aralen flagyl grisactin isoniazid myambutol pyrazinamide sporanox tinidazole vermox abilify clozaril compazine flupenthixol geodon haldol lamictal lithobid loxitane mellaril risperdal seroquel zyprexa nicotine zyban achromycin augmentin bactrim biaxin ceclor cefepime ceftin chloromycetin cipro, ciloxan cleocin duricef floxin, ocuflox gatifloxacin ilosone keftab levaquin minomycin noroxin omnicef omnipen-n oxytetracycline rifater rulide suprax tegopen trimox vantin vibramycin zithromax advair aerolate, theo-24 brethine, bricanyl ketotifen metaproterenol proventil, ventolin serevent singulair arimidex casodex decadron eulexin femara levothroid, synthroid nolvadex provera, cycrin ultram vepesid zofran acenocoumarol aceon adalat, procardia altace atenolol amlodipine avapro caduet calan, isoptin capoten captopril hctz cardizem cardura catapres cilexetil, atacand clonidine, hctz combipres cordarone coreg coumadin cozaar dibenzyline diovan fosinopril hydrochlorothiazide hytrin hyzaar inderal ismo, imdur isordil, sorbitrate lanoxin lasix lercanidipine lopressor lotensin lozol micardis minipress moduretic normadate norpace norvasc plavix plendil prinivil, zestril prinzide rythmol tenoretic tenormin trental valsartan hctz vaseretic vasodilan vasotec zebeta crestor lipitor lopid mevacor pravachol tricor zocor accupril actos alpha-lipoic acid amaryl avandia diamicron mr gliclazide metformin glucophage glucotrol glucotrol xl glucovance lyrica micronase orinase prandin precose starlix depakote dilantin lamictal neurontin sodium valproate tegretol topamax trileptal valparin aciphex asacol bentyl cinnarizine colospa compazine cromolyn sodium cytotec imodium motilium nexium nexium fast pepcid ac pepcid complete prevacid prilosec propulsid protonix reglan stugil zantac zelnorm zofran propecia, proscar famvir rebetol valtrex zovirax combivir duovir-n epivir pyrazinamide retrovir sustiva videx viramune zerit ziagen aldactone calciferol danocrine decadron prednisone provera, cycrin synthroid avodart cialis flomax hytrin levitra propecia, proscar viagra lioresal soma tizanidine ibuprofen zanaflex accupril alpha-lipoic acid amantadine aralen arcalion aricept ascorbic acid benadryl bentyl betahistine calciferol carbimazole compazine cyklokapron ddavp, stimate detrol dihydroergotoxine ditropan dramamine exelon florinef imitrex imuran isoniazid lasix melatonin myambutol nimotop orap persantine piracetam pletal quinine rifampin rifater rocaltrol strattera ticlid tiotropium urecholine urispas urso vermox zyloprim acetylsalicylic acid advil, medipren celebrex flunarizine imitrex ketorolac maxalt ponstel tylenol ultram benadryl ditropan eldepryl requip sinemet trivastal advil, medipren arava colchicine decadron feldene indocin sr mobic naprelan naprosyn zyloprim betamethasone differin nizoral oxsoralen prograf retin-a xenical advil, medipren allyloestrenol clomid, serophene diflucan evista folic acid fosamax isoflavone nexium parlodel ponstel prevacid prilosec progesterone provera, cycrin rocaltrol tibolone generic tegretol generic name: carbamazepine ; qty.
Income figures to attract differin service areas pushing and nifedipine.
Panoxyl Benzamycin Tretinoin Isotrexin Djfferin benzoyl peroxide gel 2.5%, 5%, 10% benzoyl peroxide 5% with erythromycin 3% gel cream 0.025% gel 0.025% isotretinoin 0.05%, erythromycin 2% gel adapalene 0.1% cream gel isotretinoin 0.05% gel clindamycin 1% alcoholic solution aqueous lotion erythromycin 2% alcoholic solution erythromycin 40mg, zinc acetate 12mg mL topical solution azelaic acid 20% cream benzoyl peroxide 5% gel and reminyl.
Price Tab-Cap 0.8 G TABLETS 4.50 0.0090 SCORED TABLETS 10.10 0.0101 TABLETS 20.80 0.0208 Median Price Tab-Cap 0.0101 High Low Ratio 2.31 Price Tab-Cap 1 G TABLETS 1.89 STRIP OF 10X10 TABLETS 1.91 TABLET, BLISTER PACK 0.05 0.0495 COATED TABLETS, BLISTER PACK 6.04 FILM-COATED TABLETS 6.12 Median Price Tab-Cap 0.0495 High Low Ratio 3.24 Price Tab-Cap 1 G STRIP OF 10 X TABLETS 1.00 TABLETS 1.21 TABLETS 15.33 0.0153 TABLETS 1.05 0.0350 FILM-COATED TABLETS 3.94 Median Price Tab-Cap 0.0153 High Low Ratio 3.94 4.24 6.80 Median Price Ml 0.9624 3.67 6.20 Median Price Ml 0.0494 58.40 1.10 Median Price Ml 1.3946 6.20 13.87 Median Price Ml 0.2007 Price Ml 0.5651 1.3597 Price Ml 0.0367 0.0620 Price Ml 4.6720 Price Ml 0.0550 2.7342 Price Ml 0.1240 0.2773, for instance, differkn vs retin a.
He trickiest issue for Congress concerning the pharmaceutical industry has to do with growing public pressure for a Medicare drug benefit. Everyone agrees that something has to be done to relieve senior citizens of the heavy burden of paying for prescription drugs out-of-pocket, and everyone, including the pharmaceutical industry, is on record as favoring some sort of extension of Medicare to cover outpatient prescription drugs. Widely differing versions of bills to provide such coverage passed the House and Senate this year, but could not be reconciled. The House version the one favored by the pharmaceutical industry ; proposed that coverage for prescriptions be paid in part by a set contribution from Medicare administered through private insurers. The Senate version was more generous, and provided for direct reimbursements by Medicare--without the intermediary of a private insurance plan. Political posturing on both sides obscured a critical question in this debate: how much influence should the agency administering the program have on the approved list of covered drugs and on the prices paid to the manufacturers? A program administered directly through Medicare would probably drive harder bargains and involve more regulations than a program contracted out to private insurers, and these policies would very likely spread to drug benefit programs in the private sector as well. This is a prospect that the drug industry, understandably, greatly fears, and that is undoubtedly why drug companies contributed an estimated $30 million in the recent campaign, most of which went to Republican candidates and Republican-leaning special-interest groups. The Republican victory now ensures that if a Medicare prescription-drug benefit ever does emerge from the 108th Congress, it will certainly be much more to the industry's liking than the version that passed the Senate earlier this year. Like Congress, the FDA is also on the and selegiline.
Kaufmann, J. Leistungsdiagnostik: Vergleich der Ergebnisse der Laufbandirotergometrie mit einem Feldtest: Heidelberg. Betreuerin: Dr. med. B Friedmann. Polus, Y. berprfung der Validitt des portablen Spirometriegertes X1. Heidelberg: Universitt Heidelberg; 1996. Betreuerin: Dr. med. B. Friedmann. Eberth, F. Vergleich zwischen Feldstufentest und Laufbandstufentest mittels portabler Spiroergometrieeinheit. Heidelberg: Institut fr Sport und Sportwissenschaft der Universitt Heidelberg; 1998. Betreuer: B. Friedmann. Ortlieb, E. Leistungsdiagnostik im Kanurennsport: Vergleichbarkeit der Maximalleistung und Schwellenwert im Feldtest und bei Spiroergometrien auf dem Kanu- und Handkurbelergometer. Heidelberg: Institut fr Sport und Sportwissenschaft der Universitt Heidelberg; 1998. Betreuer: Friedmann, B. Rtschle, K. Kraft- und Koordinationstraining bei ber 75jhrigen Frauen nach schwerem Sturz. Heidelberg: Institut fr Sport und Sportwissenschaft der Universitt Heidelberg; 1998. Betreuer: P. Brtsch. Oppel A. Einfluss standardisierter Trainingsprogramme auf die Grundlagenausdauer bei jugendlichen Tennisspielern. Betreuer: B. Friedmann. 1999.
DIURETIC EFFICACY OF ORAL SPIRONOLACTONE WHEN USED IN CONJUNCTION WITH FUROSEMIDE IN HEALTHY ADULT GREYHOUNDS. Riordan L, Estrada A. College of Veterinary Medicine, University of Florida, Gainesville, FL. Spironolactone is an aldosterone-receptor blocker that acts at sites in the distal nephron of the renal tubules. While it is commonly used as a diuretic for the treatment of pulmonary edema, ascites, and for edema associated with nephrotic syndrome, there is no evidence of its diuretic efficacy when used in this manner. In a recent study presented at the 2004 ACVIM forum, spironolactone failed to induce diuresis when used alone in adult healthy dogs. However, because the diuretic efficacy of spironolactone is dependent on sodium delivery to the distal nephron, the use of other diuretics in conjunction with spironolactone may increase its diuretic activity. As spironolactone is most often used in conjunction with furosemide in the treatment of heart failure, it is important to determine its diuretic activity when used in conjunction with furosemide. This study was conducted to assess the diuretic efficacy of oral spironolactone when used in conjunction with oral furosemide as compared to oral furosemide alone. Six healthy, adult male Greyhounds weighing 32 to 39 were used in a randomized, crossover design with a one week washout between treatments. Dogs were randomized to receive either furosemide alone or furosemide in conjunction with spironolactone. Two 24-hour urine collections were performed on each dog via a closed collection system for five dogs and free catch for one dog. Urine output, urine electrolyte concentrations, PCV TS, serum electrolytes, serum creatinine, BUN, and body weights were determined every 6 hours during the collection period. For the two drug protocol, dogs received a mean spironolactone dose of 2.13 0.22 mg kg every 12 hours, PO. Because the maximum diuretic efficacy of spironolactone is not achieved until the third day of therapy, the drug was administered for three days prior to the 24-hour urine collection as well as on the day of the collection. Dogs received a mean furosemide dose of 3.05 0.105 mg kg every 12 hours, PO, on the day of urine collection. No significant difference was noted between the two treatment groups for total urine volume, daily excretion of electrolytes sodium, chloride, potassium, calcium ; , or change in body weight. Results of this study suggest that spironolactone has no diuretic efficacy at a dose of approximately 2 mg kg every 12 hours when used concurrently with furosemide in normal healthy male greyhounds. Further investigation, however, is warranted in dogs with heart disease in which activation of the renin-angiotensinaldosterone pathway may lead to differing results and sinemet.
Avoid using diferin with any other product that can irritate the skin, such as medicated soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices, and lime.
The MMS Team are pleased to announce the launch of a third wave of the HMMC, ten months since the announcement of the first two waves. Teams from 20 acute hospital Trusts across England are currently working together to improve medicines management services within secondary care using collaborative methodology that has been so successful in primary care. Early improvements have so far included: the significant expansion of 'self administration' and use of 'patients own drugs' schemes; improved communication between primary and secondary care; increasing documented 'medication history reviews' for medical admissions; and the ever-expanding 'green bag' schemes for the safe transfer of patients' medicines. Participation in the HMMC has so far been restricted to acute Trusts, but we are delighted that the invitation to join the next wave has been extended to include Mental Health Trusts. Overall, a total of 20 sites will be accepted onto Wave 3. The closing date for completed expressions of interest to join the programme was 18th February 2005. From those initial expressions of interest, up to 50 sites were invited to complete a formal application to the NPC to arrive no later than 21st March. From these, 20 sites will be selected to take part in the programme. We look forward to developing this next phase and the opportunity of working with, and learning from, the 20 successful teams. For further details please contact: Gill Harvey, HMMC Lead 0151 794 8050 gill.harvey npc.nhs and hytrin and differin, for example, differin without prescription.
|